marked.bio

KRAS G12D inhibitor · small molecule

HRS-4642

7 active trials across 2 of our biomarkers, targeting KRAS G12D. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
KRAS G12D 7 7 Phase 3
KRAS G12C 1 1 Phase 1/2

Sponsors

Industry sponsors leading active biomarker-selected trials of HRS-4642.

  1. Jiangsu Hengrui 4

Trials

7 of 7 trials shown

  1. HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer

    Recruiting Phase 3 Jiangsu Hengrui Started 2025Primary completion 2029-04 NCT07232875

    HRS-4642

    …ne as First-line Treatment for Advanced or Metastatic Pancreatic Adenocarcinoma Harboring KRAS G12D Mutation

    KRAS G12DKRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting

  2. An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors

    Recruiting Phase 1/2 Jiangsu Hengrui Started 2026Primary completion 2028-12 NCT07806058

    adebrelimabHRS-7172 + AG;HRS-4642

    …ocally advanced or metastatic pancreatic cancer confirmed by histology and cytology, with RAS mutation/amplification detected by tissue or blood genetic testing.

    KRAS G12CKRAS G12DPancreatic Cancer

  3. A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer

    Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University Started 2026Primary completion 2027-10 NCT07438106

    HRS-4642

    KRAS G12D mutation confirmed by tissue histology or peripheral blood testing.

    KRAS G12DLocally Advanced Pancreatic Cancer With KRAS G12D Mutation

  4. HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation

    Recruiting Phase 2 Zhejiang University Started 2026Primary completion 2027-05 NCT07240766

    HRS-4642

    Tumor tissue testing confirms KRAS G12D mutation.

    KRAS G12DBorderline Resectable Pancreatic Adenocarcinoma

  5. HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

    Recruiting Phase 2 Zhejiang University Started 2025Primary completion 2027-02 NCT06770452

    HRS-4642Nimotuzumabgemcitabinenab-paclitaxel

    3.Tumor tissue contains KRAS G12D mutation

    KRAS G12DMetastatic Pancreatic Carcinoma

  6. A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

    Active, not recruiting Phase 1/2 Jiangsu Hengrui Started 2024Primary completion 2025-12 NCT06385678

    HRS-4642adebrelimabSHR-9839pemetrexedcisplatincarboplatincetuximab

    With unresectable locally advanced or metastatic solid tumors harbouring with KRAS G12D mutation confirmed by central laboratory testing.

    KRAS G12DAdvanced KRAS G12D Mutant Solid Tumors

  7. Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

    Active, not recruiting Phase 1 Jiangsu Hengrui Started 2022Primary completion 2024-06 NCT05533463

    HRS-4642

    Histologically confirmed diagnosis of advanced solid tumor harbouring with KRAS G12D mutation

    KRAS G12DAdvanced KRAS G12D Mutant Solid Tumors